New Drug Regimen Approval for Pancreatic Cancer

A new drug regimen for certain types of pancreatic cancer received approval from the FDA, showing significant improvements in survival rates and response rates. The drug, Onivyde, is administered via IV infusion every two weeks and is considered a useful new tool in conjunction with other chemotherapies.